Warrant Pharmaceuticalsraw materialsAnother piece of good news for our business segment. Recently, our wholly-owned subsidiary, Hunan Huana Pharmaceutical Chiral Drugs Co., Ltd., received a Good Manufacturing Practice (GMP) certification from the Brazilian National Health Surveillance Agency (ANVISA). This marks the first time our API (Active Pharmaceutical Ingredient ) business segment has passed an official audit in Brazil, signifying that our quality management and production systems continue to meet high international standards and laying a solid foundation for further expansion into the international market.

The product undergoing official audit in Brazil is fosfomycin tromethamine. It is the raw material for fosfomycin tromethamine powder and other formulations, which are mainly used to treat acute uncomplicated urinary tract infections and asymptomatic bacteriuria caused by susceptible Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter spp., Enterobacter spp., and Proteus mirabilis.

During the five-day inspection, Brazilian auditing officials conducted a comprehensive audit of the company's active pharmaceutical ingredient, fosfomycin tromethamine. They conducted an in-depth, detailed, and professional assessment of the company's production, quality control and quality assurance, utilities, and warehousing systems, and highly commended the company's outstanding performance in meeting international standards and its ability to continuously improve.

The company's active pharmaceutical ingredient, fosfomycin tromethamine, has passed the GMP certification of the Brazilian National Health Surveillance Agency to a high standard, which has created conditions for the product to successfully enter the Brazilian market, laid the foundation for its further expansion into the Brazilian market and other international markets, and is conducive to enhancing the company's international competitiveness.

This successful audit by Brazilian authorities, meeting high standards, marks a significant milestone in Warrant Pharmaceuticals' internationalization strategy. Currently, Warrant Pharmaceuticals has several products that have completed international registration, and the company will continue to enrich its product pipeline, striving to build a high-end pharmaceutical industrialization platform with a competitive edge in the international market.

https://finance.eastmoney.com/a/202603023658341485.html